
Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc.(ATOS)内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签;可在本季度与近12个月之间切换;下方为季度图与交易明细。
SEC EDGAR · FMP · ATOS · 截至 2026年6月9日
活动摘要
买入笔数
1
P-Purchase only
卖出笔数
0
近12个月
买卖比
∞
Buy/Sell (by trades)
整体情绪
Atossa Therapeutics, Inc.内部人在过去近12个月净买入股份,可能反映对公司前景的信心。
▸ 数据来源:SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
ATOS 季度内部人买卖趋势
ATOS 内幕交易卖出 · ATOS 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源:SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · ATOS CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
ATOS 高管卖出股份 · ATOS 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 12, 2026 | Steinhart Richard I Director | Award | 10,000 | — | Form 4 |
| May 12, 2026 | Chen Shu-Chih Director | Award | 10,000 | — | Form 4 |
| May 12, 2026 | Remmel H. Lawrence Director | Award | 10,000 | — | Form 4 |
| May 12, 2026 | Finn Jonathan Director | Award | 10,000 | — | Form 4 |
| May 12, 2026 | Galli Stephen J Director | Award | 10,000 | — | Form 4 |
| May 12, 2026 | Cigler Tessa Director | Award | 10,000 | — | Form 4 |
| Mar 27, 2026 | QUAY STEVEN C President & CEO · Director | Award | 65,000 | — | Form 4 |
| Mar 26, 2026 | Daniel Mark James CFO | Award | 63,000 | — | Form 4 |
| Jan 20, 2026 | QUAY STEVEN C President & CEO · Director | Award | 325,203 | — | Form 4 |
| May 21, 2025 | QUAY STEVEN C President & CEO · Director | Purchase | 11,239 | $10K | Form 4 |
| Mar 26, 2025 | Remmel H. Lawrence Director | Purchase | 10,000 | $7K | Form 4 |
| Apr 10, 2024 | Finn Jonathan Director | Purchase | 25,000 | $44K | Form 4 |
| Nov 15, 2023 | WEAVER GREGORY L Former EVP, CFO, & Director | Sale | 50,000 | $33K | Form 4 |
| Jun 20, 2023 | WEAVER GREGORY L EVP & CFO · Director | Purchase | 50,000 | $49K | Form 4 |
| Jul 2, 2021 | WEAVER GREGORY L Director | Option | 70,000 | $119K | Form 4 |
| Jul 2, 2021 | WEAVER GREGORY L Director | Other | 57,084 | $365K | Form 4 |
| Jul 2, 2021 | WEAVER GREGORY L Director | Option | 45,000 | $113K | Form 4 |
| Jul 2, 2021 | WEAVER GREGORY L Director | Option | 45,000 | $107K | Form 4 |
| Jul 2, 2021 | WEAVER GREGORY L Director | Option | 4,581 | $26K | Form 4 |
| Jul 2, 2021 | WEAVER GREGORY L Director | Sale | 107,497 | $600K | Form 4 |
▸ 数据来源:SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 ATOS 内幕交易
ATOS 内幕交易
Atossa Therapeutics, Inc.(ATOS)内幕交易数据来源于公司内部人(包括QUAY STEVEN C (President & CEO · Director), Steinhart Richard I (Director), Chen Shu-Chih (Director))提交的SEC Form 4申报文件。过去12个月内,5位内部人向SEC提交了交易申报。ATOS内部人近期主要在买入,这可能反映预设的10b5-1计划执行,而非方向性判断。
如需查看Atossa Therapeutics, Inc.机构持仓比例和内部人持股百分比,请访问持仓(Ownership)标签页 → Ownership tab →
常见问题
ATOS 内幕交易 · 5个问题Atossa Therapeutics, Inc.(ATOS)的内部人包括高管和董事,如QUAY STEVEN C (President & CEO · Director), Steinhart Richard I (Director), Chen Shu-Chih (Director)等。过去12个月内,5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源:FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026